Active, not recruitingPhase 3NCT05331183
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Intervention
- ELX/TEZ/IVA(drug)
- Enrollment
- 297 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2022 – 2027
Study locations (30)
- Medizinische Universität Innsbruck - Heilstättenschule Universitätsklinik, Innsbruck, Austria
- CUB Hôpital Erasme, Brussels, Belgium
- UZ Brussel - Campus Jette, Brussels, Belgium
- Universitair Ziekenhuis Antwerpen (UZA) - Antwerp University Hospital, Edegem, Belgium
- Universitair Ziekenhuis Gent, Ghent, Belgium
- Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium
- Universite Catholique de Louvain - Pulmonology, Woluwe-Saint-Lambert, Belgium
- Stollery Children's Hospital, Edmonton, Canada
- Le Centre de recherche du CHUM (CRCHUM), Montreal, Canada
- McGill University Health Centre, Glen Site, Montreal Children's Hospital, Montreal, Canada
- Hospital for Sick Children - Pulmonology, Toronto, Canada
- British Columbia Children's Hospital, Vancouver, Canada
- St. Paul's Hospital - Pulmonology, Vancouver, Canada
- Klinika Detskych Infekcnich Nemoci, Brno, Czechia
- Motol University Hospital, Prague, Czechia
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05331183 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.
- RECRUITINGPHASE1NCT07283770Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNCT07363304Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.Meyer Children's Hospital IRCCS